Radium 223 Dichloride (Xofigo)®

Common name: Radium 223 Dichloride
Brand name: Xofigo®
 

What is Radium 223 Dichloride?


Radium 223 Dichloride is a radiopharmaceutical that is used to treat patients with castration-resistant prostate cancer which has spread to the bones, but has not spread to other organs in the body.
 

How is Radium 223 Dichloride administered?


Radium 223 Dichloride is administered by injection.
 

What are possible side effects of this treatment?


Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are the most common side effects experienced by those who received radium 223 dichloride. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Nausea
  • Diarrhea
  • Vomiting
  • Swelling of the arms or legs
  • Low blood cell count
 

Is Radium 223 Dichloride covered in my province or territory?

Radium 223 Dichloride is covered by provincial drug programs in:
 
  • British Columbia (special authorization)
  • Ontario
 
Radium 223 Dichloride is not covered by provincial drug programs in:
 
  • Alberta
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Nunavut
  • Northwest Territories
  • Yukon
 
Last Reviewed: March 2015




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive